{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:19:24Z","timestamp":1791839964931,"version":"4.3.4"},"reference-count":158,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovaderm"},{"name":"Leo Pharma"},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]},{"name":"LEO Pharmaceuticals"},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"XenoPort"},{"name":"Anacor"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Neothetics"},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Symbio"},{"name":"Maruho"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BMS"},{"name":"Boehringer"},{"DOI":"10.13039\/100013988","name":"Dermira","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovaderm"},{"name":"Janssen"},{"name":"Kadmon"},{"name":"Kyowa"},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Paraxel"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaci.2018.08.022","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T14:23:41Z","timestamp":1536157421000},"page":"155-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":660,"title":["Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis"],"prefix":"10.1016","volume":"143","author":[{"given":"Emma","family":"Guttman-Yassky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"Su\u00e1rez-Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitokazu","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suprun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Menter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.H.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer D.","family":"D. Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2018.08.022_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cyto.2014.11.023","article-title":"New pathogenic and therapeutic paradigms in atopic dermatitis","volume":"73","author":"Malajian","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2018.08.022_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/14712598.2013.758708","article-title":"New era of biological therapeutics in atopic dermatitis","volume":"13","author":"Guttman-Yassky","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaci.2018.08.022_bib3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1203475416670364","article-title":"Review of systemic treatment options for adult atopic dermatitis","volume":"21","author":"Gooderham","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2018.08.022_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00403-015-1550-6","article-title":"Unravelling the complex genetic background of atopic dermatitis: from genetic association results towards novel therapeutic strategies","volume":"307","author":"Hoffjan","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2018.08.022_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2310\/6620.2007.06034","article-title":"A population-based survey of eczema prevalence in the United States","volume":"18","author":"Hanifin","year":"2007","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2018.08.022_bib7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2015.08.027","article-title":"Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis","volume":"137","author":"Czarnowicki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaci.2015.03.032","article-title":"Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis [letter]","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib10","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2016.04.052","article-title":"Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development [letter]","volume":"138","author":"Esaki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.amjmed.2015.05.041","article-title":"Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis","volume":"128","author":"Hjuler","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib13","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/all.12685","article-title":"Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies","volume":"70","author":"Silverberg","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2011.10694.x","article-title":"Association between atopic dermatitis and obesity in adulthood","volume":"166","author":"Silverberg","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2014.12.013","article-title":"Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis","volume":"72","author":"Zhang","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jpeds.2015.10.077","article-title":"The financial and emotional impact of atopic dermatitis on children and their families","volume":"169","author":"Filanovsky","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2018.08.022_bib18","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/03007995.2016.1195733","article-title":"The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey","volume":"32","author":"Whiteley","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2018.08.022_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2009.11.008","article-title":"An update on the genetics of atopic dermatitis: scratching the surface in 2009","volume":"125","author":"Barnes","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib21","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"MacDonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2018.08.022_bib22","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2018.08.022_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2018.08.022_bib26","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib27","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2018.08.022_bib28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib29","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2018.08.022_bib31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2018.08.022_bib32","unstructured":"Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et\u00a0al. Dupilumab efficacy and safety in adult patients with active eosinophilic esophagitis: a randomized double-blind placebo-controlled phase 2 trial. Presented at: World Congress of Gastroenterology at ACG2017; October 13-18, 2017; Orlando, FL."},{"key":"10.1016\/j.jaci.2018.08.022_bib33","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib34","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A\u00a0antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib36","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Birrell C, Kell C, et\u00a0al. A\u00a0phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD). Poster presented at: 75th Annual Meeting of the American Academy of Dermatology; March 3-7, 2017; Orlando, FL.","DOI":"10.25251\/skin.2.supp.28"},{"key":"10.1016\/j.jaci.2018.08.022_bib37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized placebo-controlled phase 2, trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"issue":"suppl 4","key":"10.1016\/j.jaci.2018.08.022_bib39","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of AD and its reversibility with broad spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib40","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course\u2014a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaci.2018.08.022_bib41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2005.02.014","article-title":"Failure of omalizumab for treatment of severe adult atopic dermatitis","volume":"53","author":"Krathen","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000095299","article-title":"No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients","volume":"141","author":"Oldhoff","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib45","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib46","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib47","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","article-title":"Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology","volume":"133","author":"Khattri","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2014.10.037","article-title":"Identification of novel immune and barrier genes in atopic dermatitis by laser capture microdissection","volume":"135","author":"Esaki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib51","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of TH2\/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib52","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib53","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22 producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib54","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib55","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jaci.2009.09.031","article-title":"Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis","volume":"124","author":"Guttman-Yassky","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib56","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1365-2133.2007.08135.x","article-title":"Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research","volume":"157","author":"Guttman-Yassky","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2011.01.054","article-title":"Contrasting pathogenesis of atopic dermatitis and psoriasis\u2014part II: immune cell subsets and therapeutic concepts","volume":"127","author":"Guttman-Yassky","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib58","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","article-title":"Highly effective new treatments for psoriasis target the IL-23\/type 17 T cell autoimmune axis","volume":"68","author":"Kim","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib64","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib65","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib66","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"A3921147 Study Investigators. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib68","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MOP.0000000000000374","article-title":"Clinical implications of new mechanistic insights into atopic dermatitis","volume":"28","author":"Leung","year":"2016","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jaci.2018.08.022_bib69","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.coi.2011.09.007","article-title":"Advances in atopic dermatitis","volume":"23","author":"Novak","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib70","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clim.2007.11.006","article-title":"Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6","volume":"126","author":"Kim","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib71","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/jid.2008.74","article-title":"Th2 cytokines act on S100\/A11 to downregulate keratinocyte differentiation","volume":"128","author":"Howell","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib72","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib73","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/jid.2014.83","article-title":"TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents","volume":"134","author":"Danso","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib74","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.4049\/jimmunol.181.10.7420","article-title":"Low expression of the IL-23\/Th17 pathway in atopic dermatitis compared to psoriasis","volume":"181","author":"Guttman-Yassky","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib75","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.4049\/jimmunol.171.6.3262","article-title":"Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes","volume":"171","author":"Nomura","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib76","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/sj.jid.5700861","article-title":"The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on \u03b2-defensin 3","volume":"127","author":"Kisich","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib77","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib78","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.0022-202x.2001.01331.x","article-title":"Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model","volume":"116","author":"Cho","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib79","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 cytokines and atopic dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J Clin Cell Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib80","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cyto.2012.10.031","article-title":"IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in\u00a0vivo and in\u00a0vitro: relevant in the pathogenesis of atopic dermatitis","volume":"61","author":"Bao","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2018.08.022_bib81","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568010023344661","article-title":"IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies","volume":"1","author":"Izuhara","year":"2002","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib82","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib83","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1398-9995.2005.00774.x","article-title":"Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis","volume":"60","author":"Jahnz-Rozyk","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.iac.2016.08.008","article-title":"Current and future biomarkers in atopic dermatitis","volume":"37","author":"Thijs","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2018.08.022_bib85","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1398-9995.1997.tb00180.x","article-title":"Monitoring of serologic immune parameters in inflammatory skin diseases","volume":"52","author":"Gebhardt","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib86","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjd.12943","article-title":"Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis","volume":"171","author":"Kou","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib87","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1399-3038.2011.01174.x","article-title":"Exploring CCL18, eczema severity and atopy","volume":"22","author":"Hon","year":"2011","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib88","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"Hijnen","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib89","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2018.08.022_bib90","doi-asserted-by":"crossref","first-page":"e0156077","DOI":"10.1371\/journal.pone.0156077","article-title":"IgE sensitization profiles differ between adult patients with severe and moderate atopic dermatitis","volume":"11","author":"Mittermann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2018.08.022_bib91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/all.13260","article-title":"House dust mites as potential carriers for IgE sensitization to bacterial antigens","volume":"73","author":"Dzoro","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib92","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/jdv.12891","article-title":"Sensitization to aeroallergens in atopic dermatitis patients: association with concomitant allergic diseases","volume":"29","author":"\u010celakovsk\u00e1","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2018.08.022_bib93","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mai.2001.111146","article-title":"House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program","volume":"107","author":"Huss","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.23822\/EurAnnACI.1764-1489.06","article-title":"Assessment of allergen-specific IgE by immunoblotting method in atopic dermatitis","volume":"49","author":"Bonyadi","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib95","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.2012.02559.x","article-title":"Chronic rhinosinusitis and asthma: novel understanding of the role of IgE \u2018above atopy\u2019","volume":"272","author":"Bachert","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib96","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2008.08984.x","article-title":"Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study","volume":"160","author":"Gambichler","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib97","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/all.12711","article-title":"IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A\u00a0treatment","volume":"71","author":"Lucae","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib98","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2310\/6620.2007.06025","article-title":"Cyclosporin A\u00a0treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients","volume":"18","author":"Hijnen","year":"2007","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2018.08.022_bib99","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt.15.69","article-title":"Drug evaluation review: dupilumab in atopic dermatitis","volume":"7","author":"Hamilton","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaci.2018.08.022_bib100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaci.2015.12.1323","article-title":"A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis","volume":"138","author":"Brunner","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib101","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/exd.13148","article-title":"Patch testing of food allergens promotes Th17 and Th2 responses with increased IL-33: a pilot study","volume":"26","author":"Ungar","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib102","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaip.2014.03.013","article-title":"Clinical reactivity to hazelnut may be better identified by component testing than traditional testing methods","volume":"2","author":"Kattan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2018.08.022_bib103","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1471-2105-6-294","article-title":"Harshlight: a \u201ccorrective make-up\u201d program for microarray chips","volume":"6","author":"Su\u00e1rez-Fari\u00f1as","year":"2005","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jaci.2018.08.022_bib104","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1198\/016214504000000683","article-title":"A model-based background adjustment for oligonucleotide expression arrays","volume":"99","author":"Wu","year":"2004","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jaci.2018.08.022_bib105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"10.1016\/j.jaci.2018.08.022_bib106","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jaci.2018.08.022_bib107","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12920-015-0133-x","article-title":"Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways","volume":"8","author":"Ewald","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jaci.2018.08.022_bib108","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","article-title":"Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response","volume":"134","author":"Dhingra","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib109","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajhg.2014.12.004","article-title":"Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms","volume":"96","author":"Baurecht","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2018.08.022_bib110","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib111","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature14154","article-title":"Super-enhancers delineate disease-associated regulatory nodes in T cells","volume":"520","author":"Vahedi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2018.08.022_bib112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.iac.2014.09.014","article-title":"Genetics of allergic diseases","volume":"35","author":"Ortiz","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2018.08.022_bib113","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13223-016-0158-5","article-title":"Genetic and epigenetic studies of atopic dermatitis","volume":"12","author":"Bin","year":"2016","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib114","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/1346-8138.12321","article-title":"Genome-wide association studies of atopic dermatitis","volume":"41","author":"Tamari","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib115","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/ng.3424","article-title":"EArly Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis","volume":"47","author":"Paternoster","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2018.08.022_bib116","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2133.2007.07999.x","article-title":"On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis","volume":"157","author":"Hoffjan","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib117","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/hmg\/ddq019","article-title":"A milieu of regulatory elements in the epidermal differentiation complex syntenic block: implications for atopic dermatitis and psoriasis","volume":"19","author":"de Guzman Strong","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2018.08.022_bib118","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib119","doi-asserted-by":"crossref","first-page":"e79253","DOI":"10.1371\/journal.pone.0079253","article-title":"Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation","volume":"8","author":"Swindell","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2018.08.022_bib120","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib121","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/all.12339","article-title":"Systemic therapy for atopic dermatitis","volume":"69","author":"Simon","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib122","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis [response to letter]","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib123","doi-asserted-by":"crossref","first-page":"e31465","DOI":"10.1371\/journal.pone.0031465","article-title":"Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells","volume":"7","author":"Tsuda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2018.08.022_bib124","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.180.3.1913","article-title":"Identification of cellular pathways of \u201ctype 1,\u201d Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A\u00a0in psoriasis","volume":"180","author":"Haider","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib125","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/j.1398-9995.2009.02054.x","article-title":"Low-dose cyclosporine A\u00a0therapy increases the regulatory T cell population in patients with atopic dermatitis","volume":"64","author":"Brandt","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib126","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-2567.2003.01585.x","article-title":"Immunomodulatory effects of cyclosporin A\u00a0on human peripheral blood dendritic cell subsets","volume":"108","author":"Tajima","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2018.08.022_bib127","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaci.2011.02.014","article-title":"Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis","volume":"128","author":"De Benedetto","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2012.12.1563","article-title":"The cutaneous innate immune response in patients with atopic dermatitis","volume":"131","author":"Kuo","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib129","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib130","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib131","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaci.2009.12.934","article-title":"Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses","volume":"125","author":"Nograles","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib132","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/eji.200939687","article-title":"The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis","volume":"39","author":"Wolk","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib133","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.yexcr.2016.05.004","article-title":"Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin","volume":"345","author":"Donetti","year":"2016","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jaci.2018.08.022_bib134","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","article-title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis","volume":"178","author":"Sa","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2013.04.028","article-title":"The role of IL-22 and Th22 cells in human skin diseases","volume":"72","author":"Fujita","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2018.08.022_bib136","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib137","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/mi.2016.24","article-title":"Interleukin-22 regulates antimicrobial peptide expression and keratinocyte differentiation to control Staphylococcus aureus colonization of the nasal mucosa","volume":"9","author":"Mulcahy","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib138","doi-asserted-by":"crossref","first-page":"e101937","DOI":"10.1371\/journal.pone.0101937","article-title":"Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1\u03b1, TNF\u03b1 and oncostatin M","volume":"9","author":"Rabeony","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2018.08.022_bib139","doi-asserted-by":"crossref","first-page":"e0161759","DOI":"10.1371\/journal.pone.0161759","article-title":"Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17","volume":"11","author":"Yuki","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2018.08.022_bib140","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3892\/etm.2015.2939","article-title":"IL-17 promotes keratinocyte proliferation via the downregulation of C\/EBP\u03b1","volume":"11","author":"Ma","year":"2016","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jaci.2018.08.022_bib141","doi-asserted-by":"crossref","first-page":"22083","DOI":"10.1038\/srep22083","article-title":"Staphylococcus aureus-derived factors induce IL-10, IFN-\u03b3 and IL-17A-expressing FOXP3+ CD161+ T-helper cells in a partly monocyte-dependent manner","volume":"6","author":"Bj\u00f6rkander","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2018.08.022_bib142","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1172\/JCI40891","article-title":"IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice","volume":"120","author":"Cho","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2018.08.022_bib143","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1178331","article-title":"Development of monocytes, macrophages, and dendritic cells","volume":"327","author":"Geissmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jaci.2018.08.022_bib144","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.immuni.2012.10.018","article-title":"Human inflammatory dendritic cells induce Th17 cell differentiation","volume":"38","author":"Segura","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2018.08.022_bib145","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/jid.2014.51","article-title":"IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models","volume":"134","author":"Nakajima","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib146","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib147","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jaci.2016.07.013","article-title":"Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin","volume":"138","author":"Esaki","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib148","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaci.2015.05.049","article-title":"Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2\/TH1 cell imbalance, whereas adults acquire CLA(+) TH22\/TC22 cell subsets","volume":"136","author":"Czarnowicki","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib149","unstructured":"Igarashi A, Kawashima M, Etoh T, Ohtsuki M, Okuizumi K, Arima K, et\u00a0al. A\u00a0multinational phase 2b clinical trial of dupilumab in adults with atopic dermatitis [abstract]. Presented at: 115th Annual Meeting of the Japanese Dermatological Association; June 3-5, 2016; Kyoto, Japan."},{"key":"10.1016\/j.jaci.2018.08.022_bib150","unstructured":"Kataoka Y, Kabashima K, Hide M, Katoh N, Saeki H, Kawashima M, et\u00a0al. A\u00a0multinational phase 3 trial of dupilumab in adults with moderate-to-severe atopic dermatitis (SOLO 1): a Japanese subanalysis. Presented at: 117th Annual Meeting of the Japanese Dermatological Association; May 31-June 3, 2018; Hiroshima, Japan."},{"key":"10.1016\/j.jaci.2018.08.022_bib151","unstructured":"Etoh T, Imafuku S, Igarashi A, Fujita H, Arima K, Zhu X, et\u00a0al. A\u00a0multinational phase 3 clinical trial of dupilumab in adults with atopic dermatitis (CHRONOS): a Japanese subanalysis. Presented at: 117th Annual Meeting of the Japanese Dermatological Association; May 31-June 3, 2018; Hiroshima, Japan."},{"issue":"suppl 1","key":"10.1016\/j.jaci.2018.08.022_bib152","first-page":"AB 5279","article-title":"Pharmacokinetics, safety and efficacy of dupilumab in a pediatric population with moderate-to-severe atopic dermatitis: results from an open-label phase 2a trial","volume":"76","author":"Cork","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib153","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/pai.12744","article-title":"An association of periostin levels with the severity and chronicity of atopic dermatitis in children","volume":"28","author":"Sung","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib154","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0625.2009.00971.x","article-title":"CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy","volume":"19","author":"Kwon","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib155","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/1346-8138.13408","article-title":"Potential preventive effects of proactive therapy on sensitization in moderate to severe childhood atopic dermatitis: a randomized, investigator-blinded, controlled study","volume":"43","author":"Fukuie","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2018.08.022_bib156","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","article-title":"Biomarkers for atopic dermatitis: a systematic review and meta-analysis","volume":"15","author":"Thijs","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.08.022_bib157","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/all.13223","article-title":"Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues","volume":"72","author":"Brunner","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.08.022_bib158","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","article-title":"Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis","volume":"140","author":"Thijs","year":"2017","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674918312661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674918312661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:15:09Z","timestamp":1758791709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674918312661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":158,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0091674918312661"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}